1. Anticancer Activity and Protein Phosphatase 1 and 2A Inhibition of a New Generation of Cantharidin Analogues

   • Jennette A. Sakoff
   • Stephen P. Ackland
   • Adam McCluskey

   OriginalPaper Pages: 1 - 11

2. Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice

   • Lisa Polin
   • Kathryn White
   • Thomas H. Corbett

   OriginalPaper Pages: 13 - 22

3. Lack of in Vitro – in Vivo Correlation of a Novel Investigational Anticancer Agent, SH 30

   • Srinivasu Poondru
   • Ralph E. Parchment
   • Bhaskara R. Jasti

   OriginalPaper Pages: 23 - 33

4. Partial Circumvention of P-Glycoprotein-Mediated Multidrug Resistance by Doxorubicin-14-O-Hemiadipate

   • Olga V. Leontieva
   • Maria N. Preobrazhenskaya
   • Ralph J. Bernacki

   OriginalPaper Pages: 35 - 48

5. Chemotherapy-Induced Palmar-Plantar Erythrodysesthesia Syndrome – Recall Following Different Chemotherapy Agents

   • Yuk Fung Hui
   • Francis J. Giles
   • Jorge E. Cortes

   OriginalPaper Pages: 49 - 53

6. Phase I Study of JM-216 (an Oral Platinum Analogue) in Combination with Paclitaxel in Patients with Advanced Malignancies

   • Suzanne Jones
   • John Hainsworth
   • F. Anthony Greco

   OriginalPaper Pages: 55 - 61

7. Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU)

   • Patricia M. LoRusso
   • Sucharu Prakash
   • Bhaskara Jasti

   OriginalPaper Pages: 63 - 71

8. Phase I/II Study of Gemcitabine plus Vinorelbine in Non-Small Cell Lung Cancer

   • Emilio Esteban
   • Joaquin Fra
   • Angel Jimenez Lacave

   OriginalPaper Pages: 73 - 82

9. Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies

   • J.H.M. Schellens
   • B. Heinrich
   • A.R. Hanauske

   OriginalPaper Pages: 83 - 93

10. Phase II Trial of Docetaxel Chemotherapy in Patients with Incurable Adenocarcinoma of the Esophagus

    • Elisabeth I. Heath
    • Susan Urba
    • Arlene A. Forastiere

    OriginalPaper Pages: 95 - 99

11. Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Renal Cell Cancer

    • Keith M. Skubitz

    OriginalPaper Pages: 101 - 104

12. A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study

    • Robert P. Whitehead
    • Joseph M. Unger
    • Vernon K. Sondak

    OriginalPaper Pages: 105 - 111

13. Phase II Trial of Amonafide in Central Nervous System Tumors: A Southwest Oncology Group Study

    • Sarah A. Taylor
    • Cathryn Rankin
    • Kurt Jaeckle

    OriginalPaper Pages: 113 - 115

14. The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: a Southwest Oncology Group Study

    • James K. Weick
    • John J. Crowley
    • Bart Barlogie

    OriginalPaper Pages: 117 - 121

15. A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

    • David G. Pfister
    • John McCaffrey
    • Ilana Palgi

    OriginalPaper Pages: 123 - 127

16. Phase II Trial of Topotecan by Continuous Infusion in Patients with Advanced Soft Tissue Sarcomas, a SWOG Study

    • G. Thomas Budd
    • Cathryn Rankin
    • Karen Antman

    OriginalPaper Pages: 129 - 132

17. Raltitrexed (Tomudex) Administration in Patients Failing Multiple Prior Chemotherapy Regimens in Advanced Colorectal Cancer: a Pilot Study

    • N. Tsavaris
    • C. Kosmas
    • Ch. Koufos

    OriginalPaper Pages: 133 - 136

18. Instructions for Authors

    Instructions for Authors Pages: 137 - 141